Several studies have shown that suppressing the production of NETs by inhibiting the functions of PAD4 and/or GSDMD provides therapeutic or protective effects in autoimmune diseases (12, 13), suggesting that PAD4 and GSDMD can serve as potential therapeutic targets (11, 14). This evidence concerns the gene PADI4 and autoimmune disease.